Every 10-Q that Cingulate Inc. (CING) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CING and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CING filings page.
Cingulate Inc., a pre‑revenue biopharmaceutical company focused on ADHD and anxiety therapies, reported a net loss of $5.9 million for the quarter and $15.2 million for the six months ended June 30 2026, larger than the prior‑year periods. Operating cash outflow was $12.8 million in the first half.
Cash and cash equivalents increased to $28.4 million from $11.0 million at year‑end 2025, driven by a $12.0 million private placement, at‑the‑market issuances and equity sales under a Lincoln Park purchase agreement. Total liabilities fell to $9.6 million, primarily as a prior Streeterville note was extinguished and the Avondale note was partially repaid or exchanged into equity.
The FDA issued a Complete Response Letter for lead ADHD candidate CTx‑1301, requesting additional CMC information but not raising clinical safety or efficacy concerns. Management is working with its CDMO to support NDA resubmission. The company discloses substantial doubt about its ability to continue as a going concern despite current liquidity, and expects to seek additional capital. A new U.S. patent issued in June 2026 protects CTx‑1301 through December 2042.
Cingulate Inc. reported a larger net loss for the quarter ended March 31, 2026 as it funds late‑stage ADHD development and commercial preparation. Net loss widened to $9.3 million from $3.9 million a year earlier, with general and administrative costs rising sharply to $5.7 million as the company ramped pre‑commercialization spending for lead candidate CTx‑1301.
Research and development expenses were stable at about $2.2 million, reflecting a shift from clinical operations toward manufacturing and regulatory work ahead of potential approval. Cash and cash equivalents increased to $25.9 million, driven by equity raises, including a ~$12 million private placement, ATM sales and an equity line with Lincoln Park.
The company ended the quarter with $18.9 million of stockholders’ equity and $12.0 million in total liabilities, including a $6.1 million Avondale promissory note. Management believes current cash can fund operations into early 2027 but discloses substantial doubt about its ability to continue as a going concern without additional capital and successful FDA approval and commercialization of CTx‑1301.
Cingulate Inc. reported a wider Q3 2025 net loss and highlighted liquidity needs as it advances its lead ADHD candidate. The company posted a net loss of $7,341,062 for the quarter, driven by higher research and development $2,848,544 and general and administrative $3,147,291 expenses. Cash and cash equivalents were $6,118,710 as of September 30, 2025.
Stockholders’ equity stood at $3,473,686, with total liabilities of $7,045,206. Operating cash outflow for the first nine months was $13,647,893. Subsequent to quarter end, the company raised debt proceeds of $6,000,000 under a new Avondale note at 9% and continued share sales under its Lincoln Park and ATM programs. Management states cash is expected to fund operations into the second quarter of 2026 and estimates it will need approximately $9,000,000 of additional capital to support commercialization efforts through the PDUFA target action date.
The FDA accepted the NDA for CTx‑1301 with a PDUFA target action date of May 31, 2026. Shares outstanding were 6,757,070 as of November 11, 2025.